D
iarrhea is a well-documented side effect of many cancer treatments and has serious consequences that can include malnutrition, electrolyte imbalance, and immune attenuation. The severity of diarrhea may range from troublesome (grade 1) to life threatening (grade 4). 1 The pathophysiology of chemotherapy-induced diarrhea (CID) is complex. Diarrhea may involve impaired absorption in the intestine and/or excessive secretion of fluid and electrolytes throughout the gastrointestinal tract. These impairments generally result from direct biochemical toxicity and cell death of the rapidly dividing crypt cells of the gastrointestinal tract (Fig 1) . [2] [3] [4] This leads to an increased proportion of immature crypt cells, which are secretory. Corresponding damage to intestinal villi, whose role is normally to absorb fluid, results in an imbalance between absorption and secretion of fluid. In addition, inflammation leads to the secretion of factors, such as prostaglandins, leukotrienes, and cytokines, which stimulate additional fluid secretion. Thus, CID is primarily a secretory diarrhea that typically occurs within 24 to 96 hours after infusion of the chemotherapy drug. 3 Chemotherapeutic agents commonly associated with diarrhea include the following types of drugs [5] [6] [7] [8] [9] [10] [11] [12] : the fluoropyrimidines (eg, 5-fluorouracil and prodrugs of this compound, such as capecitabine), topoisomerase I inhibitors (eg, irinotecan, topotecan), and other agents (eg, cisplatin Ϯ docetaxel, oxaliplatin, cytarabine [ara-C]). The incidence of CID varies depending on the treatment in question. For example, irinotecan therapy has been shown to induce grades 3/4 diarrhea in about two thirds of patients, and 5-fluorouracil/leucovorin therapy causes grades 3/4 diarrhea in nearly 15% of patients (Table 1) . 12 Newer chemotherapeutic combinations, as well as traditional regimens, are continually being evaluated for lower toxicity and greater efficacy. In particular, fluoropyrimidines less toxic than 5-fluorouracil (eg, oral prodrugs of 5-fluorouracil) are currently under development and are being tested in combinations. Despite these improvements in symptom management, CID can still be a major toxicity associated with some of these promising therapies ( 
IMPACT OF CHEMOTHERAPY-INDUCED DIARRHEA ON PATIENTS AND TREATMENT OUTCOMES
A mong the many ways in which CID negatively impacts a patient's quality of life, discomfort and limitation of social activities are paramount to patients. Impaired quality of life may include symptoms such as depression, anxiety, low selfesteem, irregular sleep patterns, malnutrition, unnecessary travel restrictions, and increased burden on the patient's caregiver. [3] [4] [5] 15 The oncology nurse recognizes that improving quality of life for patients is an important goal in both the adjuvant and metastatic disease settings. In addition, severe diarrhea has significant physical effects on the patient, including pain, weakness, lethargy, dehydration, weight loss, electrolyte imbalance, and renal insufficiency. All of these problems, if serious enough, will require hospitalization and lead to decreased quality of life for patients. [3] [4] [5] 15 Another issue of great concern is that CID may negatively impact treatment outcome by necessitating dose reductions or treatment interruptions, which in turn can be associated with decreasing time to disease progression or shorter survival. 15 In addition, because CID is associated with increased consumption of health care resources by increasing hospitalizations, it has a substantial economic impact on both patients and health care systems. 15 
ROLE OF THE NURSE IN MANAGING CHEMOTHERAPY-INDUCED DIARRHEA

Symptom-Focused History
One of the most valuable tools for the management of CID is the initial history and physical of the patient. An example of a symptom-focused history is found in Table 2 . 4, 16 Obtaining this data is an important contribution that oncology nurses can make to overall patient care. There are several reasons why nurses are in an excellent position to perform this complete assessment. First, diarrhea Abbreviations: 5-FU, 5-fluorouracil; UFT, ftorafur plus uracil; LV, leucovorin; S-1, ftorafur plus 5-chloror-2,4-dihydroxypyridine plus potassium oxonate. *National Cancer Institute Common Toxicity Criteria grades.
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may be a difficult subject for patients to talk about with providers, and many patients may feel they are wasting the provider's time. Thus, obtaining an accurate and complete history may require intervention by the nurse, with whom the patients may feel more comfortable. In addition, fear that dose reduction may be used to alleviate symptoms may also prevent patients from discussing their diarrhea. It is important to foster open communication between the patient, family, and nurse. Oncology nurses are in a unique position to assess problems of bowel elimination through patient monitoring (Table 2 ). The patients should be made to feel comfortable discussing their stool frequency, duration, quantity, and grade. All of the above should be assessed during the history, and along with the evaluation of symptoms of dehydration and of poor nutrition. Symptoms of dehydration include increased thirst, postural lightheadedness, and decreased urine output. The patient's diet should be reviewed along with any prior therapy and current medications. A medication list needs to be evaluated by all members of the health care team for possible side effects and drug-drug interactions. The medication list should be brought to all health care visits for review.
Diarrhea-Focused Physical Exam and Laboratory Evaluation
Abdominal and perianal or peristomal exams are key to the diarrhea-focused physical exam by health care providers (Table 2) . 4, 16 The abdomen should be assessed for the presence and quality of bowel sounds. Abdominal tenderness, guarding, or rigidity should be noted. The perianal area should be evaluated for skin integrity. The oncology nurse should also carefully evaluate and assess the patient's hydration status. This includes evaluating skin turgor and mucous membranes, and performing orthostatic blood pressure measurements. Appropriate laboratory tests should include electrolytes, blood urea nitrogen, and creatinine to evaluate hydration status. Stool cultures to investigate infection should be obtained to assess for ova and parasites, fecal white cells, infection, and evidence of clostridium difficile, especially if the patient has had a recent course of antibiotic therapy. The physical exam presents an ongoing opportunity for patient education on symptom management. 4, 16 Oncology nurses are in an excellent position to provide patients and their caregivers with valuable information regarding side effect management. The nurse should review dietary guidelines and evaluate any over-the-counter medications, vitamins, or herbal preparations, along with any complementary therapies the patient may be using, to ensure that these are consistent with minimizing diarrhea.
Health Care Provider Interactions
Aside from direct contact with patients receiving chemotherapy, there are other instances when oncology nurses can significantly influence the treatment choices discussed with patients. 4, 16 For example, because the nurse may be uniquely aware of patient concerns that arise during the history and physical, he or she is in a position to advise the health care team when nonprescription therapies are not adequately controlling symptoms. This interaction can have a profound effect on maintaining proper dosing and timing of planned therapy.
CONCLUSION
I
n conclusion, all health care providers should consider the treatment of CID to be an integral part of overall disease management, because prevention and control of severe diarrhea may have a significant impact on treatment outcomes. Clearly, effective management of CID is an important issue that can improve and maintain quality of life in all patients and maximize meaningful survival in patients regardless of the extent of their disease.
